Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Corporation

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

United States Income Before Tax

United States Income Before Tax % Chg.

United States Income Before Tax Common Size

Outside of United States Income Before Tax

Outside of United States Income Before Tax % Chg.

Outside of United States Income Before Tax Common Size

Other EBT by Geography

Other EBT by Geography % Chg.

Other EBT by Geography Common Size

Total EBT by Geography

Total EBT by Geography Common Size

Total EBT by Geography % Chg.

EBT by Geography

United States Revenue

United States Revenue % Chg.

United States Revenue Common Size

Outside of United States Revenue

Outside of United States Revenue % Chg.

Outside of United States Revenue Common Size

Other Revenue by Geography

Other Revenue by Geography % Chg.

Other Revenue by Geography Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Screening Medicare Parts B & C Revenue

Screening Medicare Parts B & C Revenue % Chg.

Screening Medicare Parts B & C Revenue Common Size

Screening Commercial Revenue

Screening Commercial Revenue % Chg.

Screening Commercial Revenue Common Size

Screening Other Service Revenue

Screening Other Service Revenue % Chg.

Screening Other Service Revenue Common Size

Total Screening Revenue

Total Screening Revenue % Chg.

Total Screening Revenue Common Size

Precision Oncology Medicare Parts B & C Revenue

Precision Oncology Medicare Parts B & C Revenue % Chg.

Precision Oncology Medicare Parts B & C Revenue Common Size

Precision Oncology Commercial Revenue

Precision Oncology Commercial Revenue % Chg.

Precision Oncology Commercial Revenue Common Size

Precision Oncology International Revenue

Precision Oncology International Revenue % Chg.

Precision Oncology International Revenue Common Size

Precision Oncology Other Service Revenue

Precision Oncology Other Service Revenue % Chg.

Precision Oncology Other Service Revenue Common Size

Total Precision Oncology Revenue

Total Precision Oncology Revenue % Chg.

Total Precision Oncology Revenue Common Size

COVID-19 Testing Revenue

COVID-19 Testing Revenue % Chg.

COVID-19 Testing Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue by Geography	LTM	Dec '24	Dec '23
United States Revenue	2,868	2,569.8	2,346.5
Outside of United States Revenue	214	189.1	153.3
Other Revenue by Geography	—	—	—
Total Revenue by Geography	3,082	2,758.9	2,499.8

Revenue	LTM	Dec '24	Dec '23
Screening Medicare Parts B & C Revenue	881.5	776.2	701.4
Screening Commercial Revenue	1,269.4	1,118.3	992.2
Screening Other Service Revenue	236.4	209.4	171.1
Total Screening Revenue	2,387.3	2,103.9	1,864.7
Precision Oncology Medicare Parts B & C Revenue	190.1	187.9	188.7
Precision Oncology Commercial Revenue	193.7	190.6	181.3
Precision Oncology International Revenue	214	189.1	153.3
Precision Oncology Other Service Revenue	96.9	87.4	105.8
Total Precision Oncology Revenue	694.7	655	629.1
COVID-19 Testing Revenue	—	—	6
Other Revenue	—	—	—
Total Revenue	3,082	2,758.9	2,499.8

EBT by Geography	LTM	Dec '24	Dec '23
United States Income Before Tax	—	-1,036.3	-204.1
Outside of United States Income Before Tax	—	0.1	2.4
Other EBT by Geography	—	—	—
Total EBT by Geography	-984.9	-1,036.2	-201.7